ARTICLE | Company News
Mylan, Teva autoimmune news
September 7, 2015 7:00 AM UTC
The Patent Trials and Appeals Board (PTAB) of the U.S. Patent and Trademark Office instituted inter partes review (IPR) proceedings challenging two patents that cover Teva’s thrice-weekly formulation ...